NOXAFIL POWDERMIX KIT

PeakSM

posaconazole

NDAORALFOR SUSPENSION, DELAYED RELEASE
Approved
May 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

12.1 Mechanism of Action Posaconazole is an azole antifungal agent [see ] . 12.2 Pharmacodynamics Exposure Response Relationship: Prophylaxis of invasive Aspergillus and Candida Infections in Adults Who Are at High Risk of Developing These Infections Due to Being Severely Immunocompromised In…

Pharmacologic Class:

Azole Antifungal

Clinical Trials (5)

NCT04665037Phase 2Recruiting

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Started Feb 2022
40 enrolled
Invasive Fungal Infection
NCT04218851Phase 2Completed

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Started Jul 2020
31 enrolled
Invasive Aspergillosis
NCT05065658N/ACompleted

Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients

Started Mar 2020
249 enrolled
COVID-19 Respiratory InfectionAspergillosis
NCT03717623Phase 4Recruiting

Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants

Started Aug 2019
100 enrolled
PosaconazolePharmacokineticsInvasive Candidiases+4 more
NCT03614455Phase 1Completed

Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Started Jul 2018
36 enrolled
Pharmacokinetics